Abstract

Magnetic resonance imaging (MRI) has become an important tool to study the correlation between the imaging phenotypes and the molecular profiles of Glioblastoma multiforme (GBM), the most frequent and lethal brain tumor. This type of study is named “Radiogenomics”. Currently, many radiogenomics studies segmented the tumors manually and then extracted hand-crafted MRI features for analysis. Automated segmentation approach as well as automatically learned features are urgently needed to release the burden of manual operation. In this study, we developed a predictive model, named DeepRA, based on deep imaging features and machine learning technologies to identify MRI signatures that enable accurate prediction of GBM molecular subtype and patient overall survival. We here for the first time used state-of-the-art deep imaging features to predict both molecular subtype and overall survival. We converted the high-dimensional deep feature representations to interpretable feature vector, selected the most distinguishing features and conducted the prediction. Experiments validated on The Cancer Genome Atlas (TCGA) data have shown that the DeepRA outperformed the traditional hand-crafted method. Also, compared with the regular convolutional neural networks used to segment tumors, the DeepRA presents a better performance, which shows the features extracted from DeepRA are more predictive. The implementation of the proposed method is available at https://github.com/RanSuLab/GBM-subtype-survival.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.